[go: up one dir, main page]

PE20010039A1 - Derivados de esteres del acido carbamico como agonistas y/o antagonistas del receptor metabotropico del glutamato - Google Patents

Derivados de esteres del acido carbamico como agonistas y/o antagonistas del receptor metabotropico del glutamato

Info

Publication number
PE20010039A1
PE20010039A1 PE2000000351A PE0003512000A PE20010039A1 PE 20010039 A1 PE20010039 A1 PE 20010039A1 PE 2000000351 A PE2000000351 A PE 2000000351A PE 0003512000 A PE0003512000 A PE 0003512000A PE 20010039 A1 PE20010039 A1 PE 20010039A1
Authority
PE
Peru
Prior art keywords
alkyl
carbamic acid
diphenylacetyl
alcoxyl
glutamate receptor
Prior art date
Application number
PE2000000351A
Other languages
English (en)
Inventor
Eric Vieira
Vincent Mutel
Jurgen Wichmann
Konrad Bleicher
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20010039A1 publication Critical patent/PE20010039A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/90—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated
    • C07C233/91—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated with carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/10—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups being part of any of the groups, X being a hetero atom, Y being any atom, e.g., N-acyl-thiocarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
    • C07D335/12—Thioxanthenes
    • C07D335/14—Thioxanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A DERIVADOS DE ESTERES DEL ACIDO CARBAMICO DE FORMULA I, DONDE: R1 ES H, ALQUILO; R2 Y R2` SON H, ALQUILO, ALCOXILO, HALOGENO, TRIFLUOROMETILO; X ES O, S, DOS H QUE NO FORMAN PUENTE; A1 Y A2 SON FENILO, HETEROCICLO DE 6 MIEMBROS CON 1-2 N; B ES -C(=Z)-Y-R3; R3 ES ALQUILO, ALQUENILO, ALQUINILO, BENCILO, ALQUILO-CICLOALQUILO, ALQUILO-CIANO, ALQUILO-PIRIDINILO, ALQUILO-ALCOXILO-FENILO, ENTRE OTROS; Y ES -O-,-S-, UN ENLACE; Z ES -O-, -S-; B ES EL GRUPO a, GRUPO b, ENTRE OTROS; R4 Y R5 SON H, ALQUILO, ALCOXILO, CICLOHEXILO, ALQUILO-CICLOHEXILO, TRIFLUOROMETILO; UNO DE R4 O R5 ES H. SON COMPUESTOS PREFERIDOS ESTER BUTILICO DEL ACIDO DIFENILACETIL-CARBAMICO, ESTER ETILICO DEL ACIDO DIFENILACETIL-CARBAMICO, ESTER PENT-4-INILICO DEL ACIDO DIFENILACETIL-CARBAMICO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES ANTAGONISTA O AGONISTA DEL RECEPTOR METABOTROPICO DEL GLUTAMATO Y PUEDE SER UTIL PARA EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS, PSICOSIS, ESQUIZOFRENIA, ENFERMEDAD DE ALZHEIMER, LESIONES DE MEDULA ESPINAL, HIPOXIA CAUSADA POR EL EMBARAZO, PARO CARDIACO, HIPOGLUCEMIA, RETINOPATIA
PE2000000351A 1999-04-20 2000-04-17 Derivados de esteres del acido carbamico como agonistas y/o antagonistas del receptor metabotropico del glutamato PE20010039A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99107843 1999-04-20

Publications (1)

Publication Number Publication Date
PE20010039A1 true PE20010039A1 (es) 2001-01-29

Family

ID=8238006

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000351A PE20010039A1 (es) 1999-04-20 2000-04-17 Derivados de esteres del acido carbamico como agonistas y/o antagonistas del receptor metabotropico del glutamato

Country Status (32)

Country Link
US (2) US6462198B1 (es)
EP (1) EP1171423B1 (es)
JP (1) JP3751825B2 (es)
KR (1) KR100497889B1 (es)
CN (1) CN1228337C (es)
AR (1) AR029626A1 (es)
AT (1) ATE286875T1 (es)
AU (1) AU776344B2 (es)
BR (1) BR0009885A (es)
CA (1) CA2367368C (es)
CO (1) CO5160347A1 (es)
CZ (1) CZ20013736A3 (es)
DE (1) DE60017376T2 (es)
ES (1) ES2234601T3 (es)
HK (1) HK1045683B (es)
HR (1) HRP20010761A2 (es)
HU (1) HUP0201005A3 (es)
IL (1) IL145665A (es)
MA (1) MA26781A1 (es)
MY (1) MY126586A (es)
NO (1) NO20015064L (es)
NZ (1) NZ514487A (es)
PE (1) PE20010039A1 (es)
PL (1) PL352825A1 (es)
PT (1) PT1171423E (es)
RU (1) RU2248349C2 (es)
SI (1) SI1171423T1 (es)
TR (1) TR200103010T2 (es)
TW (1) TW593241B (es)
WO (1) WO2000063166A1 (es)
YU (1) YU73001A (es)
ZA (1) ZA200107837B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005700D0 (en) * 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
IT1318636B1 (it) * 2000-07-21 2003-08-27 Roberto Pellicciari Derivati dell'acido 2- o 3- tenoico ad attivita' antagonista deirecettori del glutammato.
KR100713265B1 (ko) * 2002-12-23 2007-05-04 에프. 호프만-라 로슈 아게 ｍＧｌｕＲ１ 증강인자로서의 옥사졸
MXPA06001480A (es) * 2003-08-06 2006-05-15 Pfizer Prod Inc Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos.
NZ619746A (en) 2003-08-06 2014-05-30 Senomyx Inc Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
RU2006111093A (ru) * 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы атр-связывающих кассетных транспортеров
US20050222227A1 (en) * 2004-04-01 2005-10-06 Pfizer Inc Oxazole-amine compounds for the treatment of neurodegenerative disorders
JP4901735B2 (ja) * 2004-08-09 2012-03-21 グラクソ グループ リミテッド グルタミン酸受容体を強化する化合物および医学におけるその使用
MY158077A (en) 2005-02-04 2016-08-30 Senomyx Inc Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers tastants and taste enhancers for comestible compositions
AR055329A1 (es) 2005-06-15 2007-08-15 Senomyx Inc Amidas bis-aromaticas y sus usos como modificadores de sabor dulce, saborizantes, y realzadores de sabor
US8148536B2 (en) 2006-04-21 2012-04-03 Senomyx, Inc. Comestible compositions comprising high potency savory flavorants, and processes for producing them
RS55585B1 (sr) 2006-11-22 2017-06-30 Clinical Research Associates LLC Postupci za lečenje daunovog sindroma, krhkog x sindroma i autizma
US20080262066A1 (en) * 2007-04-20 2008-10-23 Green Cross Corporation Azole Derivatives as Cannabinoid CB1 Receptor Antagonists
CN101821256A (zh) 2007-08-02 2010-09-01 瑞蔻达蒂爱尔兰有限公司 作为mGlu5拮抗剂的新型杂环化合物
EP2093234A1 (en) 2008-02-08 2009-08-26 Nutrinova Nutrition Specialties & Food Ingredients GmbH Oligopeptides for use as taste modulators
TWI429404B (zh) 2008-03-03 2014-03-11 Senomyx Inc 異山梨醇衍生物及彼等作為風味改良劑、促味劑及促味增強劑之用途
EP2393780A1 (en) 2009-02-04 2011-12-14 Recordati Ireland Limited Heterocyclic derivatives as m-glu5 antagonists
WO2011029633A1 (en) 2009-09-14 2011-03-17 Recordati Ireland Limited Heterocyclic mglu5 antagonists
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
JP2013529673A (ja) 2010-07-09 2013-07-22 レコルダーティ アイルランド リミテッド Ｍｇｌｕ５アンタゴニストとしての新規スピロ複素環化合物
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
WO2012135522A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Process for manufacturing conjugates of improved homogeneity
ME03353B (me) 2011-03-29 2019-10-20 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
AU2013326881B2 (en) 2012-10-04 2018-08-02 Immunogen, Inc. Use of a PVDF membrane to purify cell-binding agent cytotoxic agent conjugates
KR20170088905A (ko) 2014-11-19 2017-08-02 이뮤노젠 아이엔씨 세포 결합 작용제-세포독성 작용제 접합체를 제조하기 위한 공정
WO2017121693A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Substituierte thiazol- und thiadiazolamide und ihre verwendung
RU2018130108A (ru) 2016-02-05 2020-03-06 Иммуноджен, Инк. Эффективный способ получения конъюгатов связывающийся с клеткой агент цитотоксический агент
JP7471818B2 (ja) 2016-08-18 2024-04-22 ヴィダック ファーマ リミテッド ピペラジン誘導体、医薬組成物、及びその使用方法
JP7688331B2 (ja) * 2020-09-07 2025-06-04 日産化学株式会社 １，３，４－オキサジアゾール－２－アミン化合物の製造方法
JPWO2024134942A1 (es) 2022-12-22 2024-06-27

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073566A (en) * 1989-11-30 1991-12-17 Eli Lilly And Company Angiotensin ii antagonist 1,3-imidazoles and use thereas
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
GB9626151D0 (en) 1996-12-17 1997-02-05 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
TR200103010T2 (tr) 2002-05-21
HRP20010761A2 (en) 2002-12-31
HK1045683A1 (en) 2002-12-06
NO20015064D0 (no) 2001-10-18
KR20010108518A (ko) 2001-12-07
NZ514487A (en) 2004-01-30
YU73001A (sh) 2004-09-03
PL352825A1 (en) 2003-09-08
IL145665A0 (en) 2002-06-30
AU4749200A (en) 2000-11-02
WO2000063166A1 (en) 2000-10-26
JP3751825B2 (ja) 2006-03-01
ZA200107837B (en) 2002-12-23
PT1171423E (pt) 2005-05-31
EP1171423B1 (en) 2005-01-12
TW593241B (en) 2004-06-21
HUP0201005A2 (hu) 2002-07-29
HUP0201005A3 (en) 2004-12-28
NO20015064L (no) 2001-10-18
BR0009885A (pt) 2002-01-22
MY126586A (en) 2006-10-31
EP1171423A1 (en) 2002-01-16
CA2367368C (en) 2009-09-01
DE60017376D1 (de) 2005-02-17
HK1045683B (zh) 2006-02-03
US6596743B2 (en) 2003-07-22
ATE286875T1 (de) 2005-01-15
DE60017376T2 (de) 2006-03-02
CN1228337C (zh) 2005-11-23
ES2234601T3 (es) 2005-07-01
CN1347406A (zh) 2002-05-01
SI1171423T1 (en) 2005-06-30
US6462198B1 (en) 2002-10-08
IL145665A (en) 2005-09-25
KR100497889B1 (ko) 2005-06-29
CO5160347A1 (es) 2002-05-30
CA2367368A1 (en) 2000-10-26
AR029626A1 (es) 2003-07-10
RU2248349C2 (ru) 2005-03-20
US20020091150A1 (en) 2002-07-11
JP2002542229A (ja) 2002-12-10
CZ20013736A3 (cs) 2002-03-13
MA26781A1 (fr) 2004-12-20
AU776344B2 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
PE20010039A1 (es) Derivados de esteres del acido carbamico como agonistas y/o antagonistas del receptor metabotropico del glutamato
PE20001088A1 (es) Compuestos derivados de tetrahidrobenzazepina
PE20010854A1 (es) USO DE DERIVADOS DE PIRIMIDINA 4 SUSTITUIDOS COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO mGluR1
PE20050429A1 (es) Derivados de 2-fenilamino-4-amino-pirimidina como inhibidores de quinasa, composicion farmaceutica que los contiene y proceso de preparacion
PE1998A1 (es) DERIVADOS DE BENZO [g] QUINOLINA
PE20040687A1 (es) Quinolinas sustituidas como antagonistas del receptor ccr5
AR004516A1 (es) Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen
PE20031011A1 (es) Derivados de dihidrobenzodiazepin-2-ona-iii
PE106499A1 (es) Antagonistas del receptor ccr-3
PE20040583A1 (es) Nuevos derivados de benzimidazol
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
PE20080345A1 (es) Derivados de piperazina como agonistas del receptor de gpr38
PE20020720A1 (es) Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa
PE20020258A1 (es) Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina 1 (nk-1)
PE20010681A1 (es) Derivados de benzodiazepina como antagonistas del receptor de glutamato metabotropico
PE20050525A1 (es) Derivados de pirazol sustituido y compuestos relacionados como antagonistas del receptor de bradiquinina b1
AR031556A1 (es) Derivados de 3-(diarilmetilen)-8-azabiciclo[3.2.1] octano y composiciones farmaceuticas que los comprenden
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
KR900012911A (ko) 흥분성 아미노산 수용기 길항질 화합물
BR1100514A (pt) Processo para a preparação de compostos derivados do ácido benzimidazolino - 2 - oxo - 1 - carboxìlico; produto / composto / composição
PE20021072A1 (es) DERIVADOS DE DIHIDRO-BENZO(b) (1,4)-DIAZEPIN-2-ONA COMO ANTAGONISTAS I DE mGLUR2
PE20060589A1 (es) FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b
PE20011212A1 (es) Compuestos para el tratamiento de la fibromialgia y el sindrome de fatiga cronica
PE20040698A1 (es) Derivados de isoindolina
ATE125808T1 (de) Indolederivate und ihre verwendung als serotonin- antagoniste.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed